BACKGROUND: @entity4262 ( @entity4262 ) is characterized by the triad of @entity18299 ( @entity18299 ), @entity4903 , and caf  -au-lait skin pigmentation. Ninety percent of @entity4262 @entity1 have @entity82 ( @entity82 ) @entity2122 . @entity2530 of the jaw (ONJ) has been described as an adverse side effect of @entity5520 therapy. The aim of the study was to investigate evidence of clinical and/or radiological signs of ONJ in @entity82 / @entity4262 pediatric @entity1 due to @entity5520 therapy and describe odontoiatric tools in this population. METHODS: Thirteen @entity82 / @entity4262 @entity1 were enrolled. All @entity1 during pediatric age have been treated with @entity5279 infusions. They underwent complete oral clinical examination. Ortopantomography and/or CT were evaluated in all cases. RESULTS AND CONCLUSIONS: No @entity1 developed ONJ. None of them showed radiological signs different from jaw @entity82 . In spite of the low number of @entity1 enrolled, results confirm that, in this population, ONJ can be ruled out as a chronic adverse side effect of @entity5520 therapy.

Odontoiatric perspectives and @entity2530 of the jaw as a possible adverse effect of bisphosphonates therapy in @entity82 and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2122 :: ('MESH:D019465', 'Disease') :: ['craniofacial lesions'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous dysplasia', 'FD'] @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate'] @entity18299 :: ('MESH:D001848', 'Disease') :: ['PFD', 'polyostotic bone fibrous dysplasia'] @entity4262 :: ('MESH:D005359', 'Disease') :: ['MAS', 'McCune-Albright syndrome'] @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate'] @entity4903 :: ('MESH:D004700', 'Disease') :: ['endocrine disorders'] @entity2530 :: ('MESH:D010020', 'Disease') :: ['Osteonecrosis']
@entity4262 :: (MESH:D005359,Disease) :: ['McCune-Albright syndrome']
